Roche Holding AG (RHHBY)

OTCMKTS · Delayed Price · Currency is USD
41.01
+0.24 (0.59%)
Sep 2, 2025, 3:59 PM EDT
0.59%
Market Cap280.40B
Revenue (ttm)79.83B
Net Income (ttm)11.86B
Shares Outn/a
EPS (ttm)14.77
PE Ratio23.65
Forward PE13.80
Dividend0.87 (2.14%)
Ex-Dividend DateMar 28, 2025
Volume937,708
Average Volume1,480,065
Open40.82
Previous Close40.77
Day's Range40.71 - 41.07
52-Week Range34.10 - 44.31
Beta0.17
RSI59.16
Earnings DateOct 20, 2025

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]

Sector Healthcare
Founded 1896
Employees 103,249
Stock Exchange OTCMKTS
Ticker Symbol RHHBY
Full Company Profile

Financial Performance

In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.

Financial numbers in CHF Financial Statements

News

Three Dividend Funds with Foreign Flair

This month's trio includes an unofficial dividend aristocrat.

12 hours ago - Morningstar

Alnylam (ALNY) Advances with Roche on Phase 3 Cardiovascular Trial for Zilebesiran

Alnylam (ALNY) Advances with Roche on Phase 3 Cardiovascular Trial for Zilebesiran

3 days ago - GuruFocus

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for ...

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension | RHHBY Stock News

3 days ago - GuruFocus

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardio...

3 days ago - Business Wire

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

Basel, 30 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam (Nasdaq: ALNY) today announced the decision to initiate a Phase III cardiovascular outcomes trial (CVOT) to evaluate the ability ...

3 days ago - GlobeNewsWire

Analog Devices Chair & CEO Trades $5.09M In Company Stock

It was reported on August 28, that VINCENT ROCHE , Chair & CEO at Analog Devices (NASDAQ: ADI) executed a significant insider sell, according to an SEC filing. What Happened: ROCHE's recent Form 4 fi...

4 days ago - Benzinga

Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA

Basel, 25 August 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant d...

8 days ago - GlobeNewsWire

Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina

HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina. Th...

8 days ago - Business Wire

“Walk in My Shoes” Spotlights the Invisible Struggles of People Living with Multiple Sclerosis (MS) – a Public Health Awareness Initiative by Roche in Collaboration with Multiple Sclerosis Society of India (MSSI)

Roche Pharma India, in collaboration with the Multiple Sclerosis Society of India (MSSI) presents Walk In My Shoes – a public health awareness initiative to highlight the often invisible struggles of ...

10 days ago - Business Upturn

Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™

Delray Beach, FL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence of vision-threatening di...

15 days ago - Benzinga

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free surviva...

15 days ago - Benzinga

Pennsylvania Rep. Daniel Meuser Sold Up to $1.50M Worth of NVIDIA Stock

A August filing shows that Representative Daniel Meuser reported a sale in NVIDIA (NASDAQ: NVDA), valued between $750,002 and $1,500,000. The transaction date is listed as October 1, 2024, with the r...

19 days ago - Benzinga

Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma

EPALINGES, Switzerland--(BUSINESS WIRE)-- #HCC--Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma.

20 days ago - Business Wire

Swiss government to meet pharma firms to discuss US tariffs

The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower their prices, as Switzerland seeks to negotiate down a new 39% tariff on it...

22 days ago - Reuters

Swiss Government Engages Roche and Novartis on U.S. Tariff Impact

Swiss Government Engages Roche and Novartis on U.S. Tariff Impact

23 days ago - GuruFocus

Roche's Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III A...

4 weeks ago - GlobeNewsWire

Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase II...

4 weeks ago - Business Wire

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

4 weeks ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

4 weeks ago - CNBC Television

Trump's pharmaceutical tariffs could affect some drugmakers more than others

AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.

5 weeks ago - CNBC

U.S. and European Union trade deal could cost the pharma industry up to $19 billion

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...

5 weeks ago - Fast Company

EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...

5 weeks ago - Reuters

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

FDA probes Elevidys after an 8-year-old's death in Brazil; Sarepta and Roche say the death was unrelated to gene therapy treatment. Latest Ratings ... Full story available on Benzinga.com

5 weeks ago - Benzinga